Home > Press > AlphaRx CEO Michael Lee Buys 1,000,000 Company Shares
The chief executive of AlphaRx , Michael Lee, announced In a U.S. Securities and Exchange Commission filing, that he has concluded his purchase of 1,000,000 shares of his company for an average price of $0.17, increasing his holdings to about 11,327,866 shares or 13% of the company. Lee said following the purchase "I strongly believe that our share price is severely undervalued given the progress we have demonstrated in our Nanotechnology Drug Delivery Platform." 'Vansolin', Lee noted, intended for the treatment of noscomial pneumonia, is now on track to enter into human trials in 2008 and has a potential market value of US$3.6 billion. Lee concluded his comments by saying "we have four Nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars."
AlphaRx CEO Michael Lee Buys 1,000,000 Company Shares
MARKHAM, ON, Canada | Posted on November 29th, 2007
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Director, Market & Business Development
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Pixelligent Closes $5.5 Million in Funding: Capital Will Be Used to Support Global Customer Growth December 12th, 2014
Nanometrics Announces Upcoming Investor Events November 19th, 2014
Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014
Arrowhead to Present at Upcoming Conferences November 15th, 2014
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014
Unraveling the light of fireflies December 17th, 2014
Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014
Instant-start computers possible with new breakthrough December 19th, 2014
Aculon Hires New Business Development Director December 19th, 2014
Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014